Search results
-
Triple meeting 2024 – Revolution shows selective KRAS promise
… (solid tumours) Venue Triple meeting 2024 ESMO 2024 ORR 30% (12/40)* 19% (5/27)** …
- 03/26/2025 - 09:29 -
Another hold for BioNTech
… & 2mg/kg Q3W (reduced from 3 & 6mg/kg Q3W) Data at ESMO 2024: ORR 25-28%, Gr≥3 TRAEs 41-46%, discontinuation …
- 10/22/2024 - 13:40 -
Transgene stumbles with its fixed immunotherapy
… in relapsed solid tumours +/- Keytruda Data at ESMO 2024: 2/6 responses with Keytruda combo TG6050 …
- 10/15/2024 - 14:26 -
J&J’s Sunrise dims
… BCG unresponsive +/- cetrelimab vs cetrelimab Data at ESMO 2024: CR 84% vs 46% with TAR-200 mono vs cetrelimab; … cystectomy + cetrelimab vs cetrelimab Data at ESMO 2024: pCR 42% vs 23% with TAR-200 + cetrelimab vs …
- 10/10/2024 - 13:12 -
J&J ramps up its bladder cancer battle
… +/- cetrelimab vs cetrelimab CR Data at ESMO 2024: CR 84% with TAR-200 mono vs 46% with cetrelimab; … cystectomy + cetrelimab vs cetrelimab pCR Data at ESMO 2024: pCR 42% with TAR-200 + cetrelimab vs 23% with …
- 04/23/2025 - 14:19 -
AbbVie has Met phase 3, again
… ORR in high cMet expressers at doses ≥2.4mg/kg); data at ESMO 2024 in GEA (29% ORR) & NSCLC (44% ORR) Ph1 …
- 02/25/2025 - 10:35 -
Shattuck exits oncology
… PD-(L)1-refractory Hodgkin’s lymphoma (Tevimbra combo) at ESMO 2024: 67% ORR (22/33 pts) Lemzoparlimab I-Mab …
- 10/02/2024 - 10:58 -
ESMO 2024 – Regeneron's fianlimab do-over
ESMO 2024 – Regeneron's fianlimab do-over …
- 09/23/2024 - 21:34 -
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses … degraders in focus Prelude led the biotech fallers, but ESMO 2024 might be better remembered for the latest collapse … September, its last day of formal presentations. ESMO 2024 risers Company Share movement* …
- 09/20/2024 - 15:01 -
ESMO 2024 – Amgen’s PRMT5 still looks lacklustre
ESMO 2024 – Amgen’s PRMT5 still looks lacklustre … 193 in phase 1/2 Triple Meeting 2023 ESMO 2024 presentation Cutoff date 1 Sep 2023 …
- 09/17/2024 - 12:26
